iwNHL 2015 | Determining effective combinations of immune checkpoint inhibitors for lymphoma

Name: Determining effective combinations of immune checkpoint inhibitors for lymphoma
Uploaded: 2015-10-03T00:00:00.000Z
Duration: 3 min 30 s
Description: At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Stephen M. Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the clinical development of combination approaches with immune checkpoint inhibitors for the treatment of patients with non-Hodgkin and Hodgkin lymphoma. Challenges and directions for future trials with this approach are also proposed.

Stephen Ansell • 3 Oct 2015

iwNHL 2015

Hodgkin Lymphoma Non-Hodgkin Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Ibrutinib Ipilimumab Nivolumab Pembrolizumab

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Stephen M. Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the clinical development of combination approaches with immune checkpoint inhibitors for the treatment of patients with non-Hodgkin and Hodgkin lymphoma. Challenges and directions for future trials with this approach are also proposed.